CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS

Abstract: The present invention relates to hitherto unknown compounds of formula (I) or their tautomeric forms, the attachment to the pyridine ring being in the 3- or 4-position, in which formula R1 stands for one or more substituents which can be the same or different and are selected from the group consisting of: hydrogen, halogen, trifluoromethyl, carboxy, C1-C4 alkyl, alkoxy or alkoxycarbonyl, nitro, amino or cyano and Q stands for C4-C20 divalent hydrocarbon radical which can be straight, branched, cyclic, saturated or unsaturated and X stands for carbonyl, carbonylamino, aminocarbonyl, oxycarbonyloxy, oxycarbonyl, carbonyloxy, aminocarbonyloxy, aminothiocarbonyloxy, oxycarbonylamino or oxythiocarbonylamino and Y stands for benzylene or phenylene and R2 stands for one or more substituents which can be the same or different and are selected from the group consisting of: hydrogen, C1-C4 alkyl, hydroxyalkyl or alkoxy, hydroxy, halogen, trifluoromethyl, cyano, carboxamido, sulfamoyl, nitro, amino, carboxy, alkoxycarbonyl or benzyloxy; and pharmaceutically acceptable, non-toxic salts and N-oxides thereof. The present compounds are of value in the human and veterinary practice.

Description: CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS This invention relates to a hitherto unknown class of compounds which shows strong activity in inhibiting undesirable cell proliferation in e.g. skin cells and cancer cells, to pharmaceutical preparations containing these compounds, to dosage units of such preparations, and to their use in the treatment and prophylaxis of diseases characterized by abnormal cell differentiation and/or cell proliferation such as e.g. psoriasis and cancer. The compounds of the present invention are represented by the general formula I or their tautomeric forms, the attachment to the pyridine ring being in the 3- or4-position, in which formula R« | stands for one or more substituents which can be the same or different and are selected from the group consisting of: hydrogen, halogen, trifluoromethyl, carboxy, C1-C4 alkyl, alkoxy or alkoxycarbonyl, nitro, amino or cyano and Q stands for C4-C20 divalent hydrocarbon radical which can be straight, branched, cyclic, saturated or unsaturated and X stands for carbonyl, carbonylamino, aminocarbonyl, oxycarbonyloxy, oxycarbonyl, carbonyloxy, aminocarbonyloxy, aminothio- carbonyloxy, oxycarbonylamino or oxythiocarbonylamino and Y stands for benzylene or phenylene and R2 stands for one or more substituents which can be the same or different and are selected from the group consisting of: hydrogen, C1-C4 alkyl, hydroxyalkyl or alkoxy, hydroxy, halogen, triflouro- methyl, cyano, carboxamido, sulfamoyl, nitro, amino, carboxy, alkoxycar- bonyl or benzyloxy. If the present compounds contain one or more asymmetric carbon atoms, these compounds may form optical isomers or diastereoisomers. The present invention also comprises such isomers, and mixtures of same. The present salts of the compounds of formula I may be formed with pharmaceutically acceptable inorganic or organic acids, such as hydrochloric, hydrobromic and hydroiodic acid, phosphoric acid, sulphuric acid, nitric acid, 4-toluenesulphonic acid, methanesulphonic acid, formic acid, acetic acid, propionic acid, citric acid, tartaric acid, succinic acid, benzoic acid and maleic acid. The present salts of the compounds of formula I may also be formed with pharmaceutically acceptable, inorganic or organic bases. Salts formed with pharmaceutically acceptable, non-toxic bases may be alkali metal salts and alkaline earth metal salts, such as lithium, sodium, potas- sium, magnesium, calcium salts, as well as salts with ammonia and suitable non-toxic amines, such as C^-Cg-alkylamines, e.g. triethylamine, C | -Cg alkanolamines, e.g. diethanolamine or triethanolamine, procaine, cycloalkylamines, e.g. dicyclohexylamine, benzylamines, e.g. N-methyl- benzylamine, N-ethylbenzylamine, N-benzyl-2-phenylethylamine, N,N'-dibenzylethylenediamine or dibenzylamine, and heterocyclic amines, e.g. morpholine, N-ethylpiperidine and the like. Even if the present compounds are well absorbed after enteral administration, in some cases it can be advantageous to prepare suitable bioreversible derivatives of compounds of the invention, i.e. to prepare so-called prodrugs, preferably derivatives, the physicochemical properties of which leads to improved solubility at physiological pH and/or absorption and/or bioavailability of the compound in question. Such derivatives are for instance pyridyl N-oxide derivatives of compounds of the invention, such compounds being prepared by oxi- dation of the pyridyl N by a suitable oxidising agent, e.g. with 3-chloro- perbenzoic acid in an inert solvent, e.g. dichloromethane. Other suitable methods to improve the physicochemical properties and/or solubility of the compounds concerned can be used as well. Λ/-Alkyl-Λ/ , -cyano-ΛΛ-pyridylguanidines, described in United King- dom Patent No. 1 ,489,879, are potent potassium channel activators with a pronounced effect as pre-capillary vasodilators, reducing the total peripheral resistance in animals and in man, and are thus useful as antihyper- tensives. As stated in International Patent No. PCT/DK93/00291 , filing date September 13, 1993 , Publication No. WO 94/06770 the introduction of aryloxy-containing radicals into the aliphatic groups from the above-cited U.K. Patent has led to structures showing more specific pharmacological effects on isolated tissues and cells and with no or a negligible effect on ^ 6 Rb-efflux from potassium channels, as compared with the established effect of compounds covered by the above-mentioned U.K. Patent. The compounds of the present invention inhibit the proliferation of various tumour cell lines in cultures at lower concentrations than the known compounds, confer tabel 1 below, thus making them potentially useful in antineoplastic chemotherapy. The inhibition of tumour cell proliferation was studied using different types of human cancer cell lines. The cell lines under investigation were small cell lung carcinoma (NYH), non small cell lung carcinoma (NCI- H460), and breast cancer (MCF-7) using the following general procedure: The cells were cultured in vitro for 24 hours in the presence of the compound under investigation. DNA synthesis was measured by incorpo- ration of [3H]thymidine, and the median inhibitory concentrations (IC50) of the compounds were calculated. Table 1. Inhibition of tumour cell proliferation in vitro in human breast cancer (MCF-7), human small cell lung carcinoma (NYH) and human non small cell lung cancer (NCI-H460) cell lines by compounds of the following examples of the present invention. Compound from MCF-7 NYH NCI-H460 IC 50 (nM) IC 50 (nM) IC 50 (nM) Example No. 2 57 6.2 66 Example No. 4 2.2 1.7 Prior art A 920 380 >1000 Prior art B 250 45 67 A: Λ/-Cyano-Λ/ , -(4-phenoxybutyl)-Λ/"-4-pyridylguanidine, in PCT/DK93/00291 , example 14. B: Λ/-Cyano-Λ/'-(5-phenoxypentyl)-Λ/"-4-pyridylguanidine, in PCT/DK93/00291 , example 18. The results show that the compounds of the present invention are able to inhibit the proliferation of tumour cells in vitro at the same or lower concentrations than the compounds A and B from PCT/DK93/00291 . The compounds of the invention are well tolerated and non- toxic and are exerting the described beneficial activities with no or minimal effect on the systemic blood pressure. In general, they may be administered by oral, intravenous, intraperitoneal, intranasal or transdermal routes. The present invention also relates to methods for preparing the desired compounds of the general formula I. The compounds of the formula I may conveniently be prepared by standard procedures detailed in the art. The routes are outlined in the following reaction scheme. -R 2 π I A = O, S or NH B = -(C=O)- or -(C=0)-0- Q, R- j , R2, X and Y are as defined above a) DCCD, NH 2 CN, Et 3 N, CH3CN, 2 weeks. (General procedure 1). b) DMAP, Et 3 N, Pyridine, 55°C, 3h. (General procedure 2). c) Pyridine, 0-5°C. (General procedure 3). The present compounds are intended for use in pharmaceutical compositions which are useful in the treatment of the above mentioned diseases. The amount required of a compound of formula (I) (hereinafter referred to as the active ingredient) for therapeutic effect will, of course, vary both with the particular compound, the route of administration and the mammal under treatment. A suitable dose of a compound of formula (I) for systemic treatment is OJ to 400 mg per kilogram bodyweight, the most preferred dosage being 1.0 to 100 mg per kg of mammal bodyweight, for example 5 to 20 mg/kg; administered once or more times daily. A daily dose (for adults) may amount to 1 mg to 10000 mg, preferably from 70 - 5000 mg, and in the veterinary practice correspondingly, in daily doses from 0J to 400 mg/kg bodyweight. While it is possible for an active ingredient to be administered alone as the raw chemical, it is preferable to present it as a pharmaceutical formulation. Conveniently, the active ingredient comprises from 0.1% to 99% by weight of the formulation. Conveniently, dosage units of a formulation contain between 0.5 mg and 1 g of the active ingredient. For topical administration, the active ingredient preferably comprises from 1% to 20% by weight of the formulation but the active ingredient may comprise as much as 50% w/w. Formulations suitable for nasal or buccal administration may comprise 0.1% to 20% w/w. for example about 2% w/w of active ingredient. By the term "dosage unit" is meant a unitary, i.e. a single dose which is capable of being administered to a patient, and which may be readily handled and packed, remaining as a physically and chemically stable unit dose comprising either the active material as such or a mixture of it with solid or liquid pharmaceutical diluents or carriers. The formulations, both for veterinary and for human medical use, of the present invention comprise an active ingredient in association with a pharmaceutically acceptable carrier therefor and optionally other therapeutic ingredient(s). The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulations and not deleterious to the recipient thereof. The formulations include those in a form suitable for oral, rectal, parenteral (including subcutaneous, intramuscular, intravenous and intra- peritoneal) administration. The formulations may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. Formulations of the present invention suitable for oral administration may be in the form of discrete units as capsules, sachets, tablets or lozenges, each containing a predetermined amount of the active ingredient; in the form of a powder or granules; in the form of a solution or a suspension in an aqueous liquid or non-aqueous liquid; or in the form of an oil-in-water emulsion or a water-in-oil emulsion. The active ingredient may also be ad- ministered in the form of a bolus, electuary or paste. Formulations for rectal administration may be in the form of a suppository incorporating the active ingredient and a carrier such as cocoa butter, or in the form of an enema. Formulations suitable for parenteral administration conveniently comprise a sterile oily or aqueous preparation of the active ingredient which is preferably isotonic with the blood of the recipient. In addition to the aforementioned ingredients, the formulations of this invention may include one or more additional ingredients, such as diluents, buffers, flavouring agents, binders, surface active agents, thickeners, lubricants, preservatives, e.g. methylhydroxybenzoate (including anti-oxidants), emulsifying agents and the like. The compositions may further contain other therapeutically active compounds usually applied in the treatment of the above mentioned pathological conditions, e.g. antineoplastic agents which may result in synergistic effects on tumour cells. The invention will now be further described in the following general procedures, preparations and examples: The exemplified compounds I are listed in table 2. Table 2. ComExample *1 3- or 4- Q X Y R 2 pound No. Pyridyl No. 101 1 H 4 (CH 2 ) 5 CONH phenyl H 102 2 H 4 (CH 2 )e NHCO phenyl H 103 3 H 4 (CH 2 )4 NH(CO)O benzyl H 104 4 H 4 (CH 2 )e O(CO) phenyl 4-CI 105 5 H 4 (CH 2 ) 6 O(CO)O phenyl 4-CI 106 6 H 4 (CH 2 ) 5 (CO)O phenyl 4-CI 107 7 H 4 (CH 2 ) 6 O(CS)NH phenyl 4-CI 108 8 H 4 (CH 2 ) 6 NHCO phenyl 4-CI 109 9 6-OCH3 3 (CH 2 ) 6 NHCO phenyl 4-CI 110 10 2-CH3 4 (CH 2 ) 6 NHCO phenyl 4-CI 111 11 H 4 (CH 2 ) 5 CO phenyl 4-CI 112 12 H 4 (CH 2 ) 7 CO phenyl 4-CI 113 13 H 4 (CH 2 ) 6 CO phenyl 4-CI All melting points are uncorrected. For ' Η and ^C nuclear magnetic resonance (NMR) spectra (300 MHz) chemical shift values (δ) are quoted, unless otherwise specified, for deuterochloroform and hexa- deuterodimethylsulfoxide solutions relative to internal chloroform (^ H NMR δ 7.25, 13 C NMR δ 76.81 ) or tetramethylsilane (δ 0.00). The value for a multiplet (m), either defined (doublet (d), triplet (t), quartet (q)) or not at the approximate mid point is given unless a range is quoted (s singlet, b broad). Chromatography was performed on silica gel. The following abbreviations and formulas are used: DCCD (Λ/./V-dicyclohexylcarbodi- imide), NH2CN (cyanamide), Et 3 N (triethylamine), CH3CN (acetonitrile), DMAP (dimethylaminopyridine), MeOH (methanol), CH2CI2 (methylene- chloride), NH3 (ammonia), CDCI3 (deuterochloroform) and DMSO-dg (hexadeuterodimethylsulfoxide). General procedure 1 : Conversion of compounds of the general formula II into compounds of the general formula I. A compound of the general formula II (5 mmol) was suspended in acetonitrile (12 ml) and dicyclohexylcarbodiimide (10 mmol), cyanamide (10 mmol) and triethylamine (0.07 ml ) was added. The reaction mixture was stirred at room temperature for 2 weeks. The reaction mixture was filtered and washed with acetonitrile. The white solid containing product and dicyclohexylthiourea was triturated with chloroform (20 ml) overnight and filtered to give the product of general formula I as white crystals. General procedure 2: Coupling of compounds of the general formula III with compounds of the general formula IV resulting in compounds of the general formula I. A compound of the general formula III (4 mmol), a compound of the general formula IV (5 mmol), triethylamine (0J2 ml) and 4-dimethylamino- pyridine (15 mg) were dissolved in pyridine (4 ml). The reaction mixture was stirred at 55°C for 3 hours and then cooled to room temperature. The product was precipitated with ether. Filtration resulted in pure product of the general formula I as white crystals. General procedure 3: Coupling of compounds of the general formula V with compounds of the general formula VI resulting in compounds of the general formula I. A compound of the general formula V (2.0 mmol) was suspended in dry pyridine (4 ml) in a two-necked flask with a three-way-tap and a septum. The air was exchanged with argon through the three-way-tap. The flask was cooled on ice and a compound of the general formula VI (3.0 mmol) was added through the septum. The reaction mixture was stirred at 0°C for 2 hours and at 5°C for 5 days. The product was purified by flash chromatography (Eluent 1 % NH 3 (aq) and 0-20% MeOH in CH Cl2) and crystallized from ether. Example 1 : /V-Cvano-/\M5-phenylaminocarbonylpentyl)-Λ/"-4-pyridylouanidine (Compound 101) General procedure 1. Starting compound II: Λ/-(5-Phenylaminocarbonylpentyl)-Λ/ , -4-pyri- dylthiourea. Purification: General procedure. 1 H NMR (DMSO-d 6 ) δ: 9.86 (s, 1 H), 9.39 (bs, 1 H), 8.37 (d, 2H), 7.85 (bs, 1 H), 7.59 (d, 2H), 7.28 (t, 2H), 7.21 (bd, 2H), 7.01 (t, 1H), 3.28 (bs, 2H), 2.32 (t, 2H), 1.59 (m, 4H), 1.35 (m, 2H). Example 2: Λ/-(6-Benzoylaminohexyπ-Λ/'-cyano-Λ/"-4-pyridylguanidine (Compound 102) General procedure 1. Starting compound II: /V-^-Benzoylaminohexy -A - pyridylthiourea. Purification: General procedure. 1 H NMR (DMSO-dg) δ: 9.40 (bs, 1H), 8.43 (t, 1H), 8.38 (d, 2H), 7.83 (m, 3H), 7.47 (m, 3H), 7.20 (m, 2H), 3.25 (q, 4H), 1.54 (m, 4H), 1.33 (m, 4H). Example 3: Λ/-(4-Benzyloxycarbonylaminobutyl)-Λ/'-cyano-Λ/"-4-pyridylguanidine (Compound 103) General procedure 2. Starting compound III: S-Methyl A/-cyano-/V-4-pyridylisothiourea. Starting compound IV: 4-Benzyloxycarbonylaminobutylamine. Purification: Flash chromatography (Eluent 0.5% NH3(aq) and 0- 20% MeOH in CH2CI2) and crystallisation from ether. 13 C NMR (DMSO-d 6 ) δ: 157.2, 156.1 , 150.0, 145.8, 137.2, 128.3, 127.6, 116.4, 114.6, 65.1 , 48.5, 41.5, 39.9, 26.7, 26.0. Example 4: Λ/-(6-(4-Chlorobenzoyloxy)hexyl)-Λ/'-cvano-Λ/"-4-pyridylguanidine (Compound 104) General procedure 3. Starting compound V: Λ/-Cyano-Λ/ , -(6-hydroxyhexyl)-Λ/"-4-pyridyl- guanidine. Starting compound VI: 4-Chlorobenzoyl chloride. Purification: General procedure. 13 C NMR (DMSO-d 6 ) δ: 164.8, 157.0, 150.0, 145.8, 138.1 , 130.9, 128.9, 128.6, 116.4, 114.5, 64.8, 41.6, 28.5, 27.9, 25.7, 25.0. Example 5: Λ/-(6-(4-Chlorophenoxycarbonyloxy)hexyl)-Λ/ , -cyano-Λ/"-4-pyridylguanidine (Compound 105) General procedure 3. Starting compound V: Λ/-Cyano-Λ/ , -(6-hydroxyhexyl)-A/"-4-pyridyl- guanidine. Starting compound VI: 4-Chlorophenyl chloroformate. Purification: General procedure. 13 C NMR (CDCI 3 ) δ: 157.7, 153.5, 150.7, 145.0, 149.6, 131.4, 129.6, 122.4, 117.1 , 116.0, 68.8, 42.4, 29.0, 28.4, 26.3, 25.3. Example 6: Λ/-(6-(4-Chlorophenoxycarbonyl)pentyl)-Λ/'-cvano-Λ/"-4-pyridylguanidine (Compound 106) Λ/-(5-Carboxypentyl)-Λ/'-cyano-Λ/"-4-pyridylguanidine (2.0 g), 4- chlorophenol (0.94 g), triethylamine (2.0 ml) and bromo-tris-pyrrolidino- phosphonium hexafluorophosphate (3.4 g) and dry dichloromethane (100 ml) were mixed and stirred overnight at room temperature. More bromo- tris-pyrrolidino-phosphonium hexafluorophosphate (0.68 g) and triethylamine (0.2 ml) was added and the reaction mixture was stirred overnight. The solvents were evaporated, the residue purified by flash chromatography (Eluent 0.5% NH 3 (aq) and 0-17% MeOH in CH 2 CI 2 ). Crystallization from ether resulted in white crystals containing both the product and a triethylammonium salt. The triethylammonium salt was removed by extraction with water resulting in the pure product. 13 C NMR (DMSO-dg) δ: 171.5, 157.1 , 150.1 , 149.1 , 145.7, 129.8, 129.3, 123.7, 116.4, 114.6, 41.5, 33.2, 28.2, 25.5, 23.8. Example 7: /V-(6-(4-Chlorophenylaminothiocarbonyloxy)hexyl)-Λ/'-cvano-Λ/"-4- pyridylguanidine (Compound 107) /V-Cyano-/V-(6-hydroxyhexyl)-Λ/"-4-pyridylguanidine (0.5 g), 4- chlorophenyl isothiocyanate (0.4 g) and diisopropylethylamine (0.32 ml) was mixed in a two-necked flask with a three-way-tap and a septum. The air was exchanged with argon through the three-way-tap. Dry pyridine (10 ml) was added through the septum. The reaction mixture was stirred for 5 days at room temperature. The product was purified by flash chromatography (Eluent 1% NH 3 (aq) and 0-10% MeOH in CH 2 CI 2 ) and crystallized from ether. 1 H NMR (DMSO-dg) δ: 11.16 (bs, 1H), 9.37 (bs, 1H), 8.38 (bd, 2H), 7.84 (bt, 1H), 7.40 (m, 4H), 7.22 (bd, 2H), 4.46 (m, 2H), 3.26 (q, 2H), 1.72 (m, 2H), 1.54 (m, 2H), 1.36 (m, 4H). Example 8: Λ/-(6-(4-Chlorobenzoylamino)hexyπ-Λ/'-cvano-Λ/"-4-pyridylguanidine (Compound 108) General procedure 2. Starting compound III: S-Methyl A/-cyano-/V-4-pyridylisothiourea. Starting compound IV: 4-Chorobenzoylaminohexylamine. Purification: Flash chromatography (Eluent 0.5% NH3(aq) and 0- 13% MeOH in CH2CI2) and crystallisation from acetone/ether. 1 3 C NMR (DMSO-d 6 ) δ: 164.9, 157.1 , 150.0, 145.8, 135.7, 133.3, 129.0, 128.2, 116.4, 114.5, 41.7, 39.1 , 28.9, 28.5, 26.0, 25.9. Example 9: Λ/-(6-(4-Chlorobenzoylamino)hexyl)-Λ/'-cvano-Λ/"-(2-methoxy- 5-pyridyl)guanidine (Compound 109) General procedure 2. Starting compound III: S-Methyl Λ/-cyano-Λ/ , -(2-methoxy-5-pyridyl)- isothiourea. Starting compound IV: 4-Chorobenzoylaminohexylamine. Purification: General procedure. 1 3 C NMR (DMSO-dg) δ: 164.9, 161.2, 158.6, 143.4, 137.0, 135.7, 133.3, 129.0, 128.2, 127.9, 117.3, 110.3, 53.2, 41.3, 39.1 , 28.9, 28.7, 26.1 , 25.8. Example 10: Λ/-(6-(4-Chlorobenzoylamino)hexyl)-Λ/'-cvano-Λ/"-(2-methyl-4- pyridvDguanidine (Compound 110) General procedure 2. Starting compound 111: S-Methyl A/-cyano-/V-(2-methyl-4-pyrid- yl)isothiourea. Starting compound IV: 4-Chorobenzoylaminohexylamine. Purification: Flash chromatography (Eluent 1% NH3(aq) and 2-10% MeOH in CH 2 CI 2 ). 1 3 C NMR (DMSO-d ) δ: 165.0, 158.4, 157.1 , 149.4, 146.0, 135.7, 133.4, 129.0, 128.2, 116.5, 113.6, 112.1 , 41.7, 28.9, 28.6, 26.1 , 25.9, 24.1. Example 11 : Λ/-(5-(4-Chlorobenzoyl)pentyl)-Λ/'-cvano-Λ/"-4-pyridylguanidine (Compound 111) General procedure 2. Starting compound III: S-Methyl A/-cyano-/V-4-pyridylisothiourea. Starting compound IV: 4-Chorobenzoylpentylamine. Purification: General procedure. 1 3 C NMR (DMSO-dg) δ: 198.9, 157.3, 149.8, 146.0, 137.9, 135.3, 129.7, 128.7, 116.4, 114.5, 41.6, 37.7, 28.5, 25.7, 23.2. Example 12: Λ/-(7-(4-Chlorobenzoyl)heptyl)-Λ/'-cvano-Λ/"-4-pyridylguanidine (Compound 112) General procedure 2. Starting compound III: S-Methyl /V-cyano-A -pyridylisothiourea. Starting compound IV: 4-Chorobenzoylheptylamine. Purification: General procedure. 1 3 C NMR (DMSO-dg) δ: 199.0, 157.0, 150.1 , 145.7, 137.8, 135.3, 129.7, 128.7, 116.3, 114.5, 41.7, 37.8, 28.5, 28.4, 26.0, 23.5 Example 13: /V-(6-(4-Chlorobenzoyl)hexyl)-Λ/'-cvano-Λ/"-4-pyridylguanidine (Compound 113) General procedure 2. Starting compound 111: S-Methyl A/-cyano-/V-4-pyridylisothiourea. Starting compound IV: 4-Chorobenzoylhexylamine. Purification: General procedure. Example 14: Capsules 1 Capsule contains: Λ/-(6-(4-Chlorobenzoyloxy)hexyl)-Λ/'-cyano- Λ/"-4-pyridylguanidine (active compound) 100 mg Polyethylene Glycol 962 mg Gelatine Capsule no. 00 Gelatine 122 mg Example 15: Tablet Manufacture of 10.000 tablets I Λ/-(6-(4-Chlorobenzoyloxy)hexyl)-Λ -cyano- Λ/"-4-pyridylguanidine (active compound) 10,000 kg Cross carmellose sodium 0,300 kg II Hydroxypropylmethyl cellulose, low viscosity type 0,200 kg Sorbimacrogol oleate 0,010 kg Purified water q.s. Ill Crosscarmellose sodium 0,200 kg Coloidal anhydrous silica 0,050 kg Magnesium stearate 0,050 kg I is mixed intimately in a highshear mixer, is wetted with II and granulated into a moist mass. The moist granulate is dried in a fluid-bed dryer at an inlet air temperature of 60°C until the dried granulate has a water activity of 0.3-0.4 (= in equilibrium with air of 30-40% R.H.). The dried granulate is passed through a sieve with mesh openings of 850 mm. The sieved granulate is finally mixed with III in a cone mixer. The finished granulate is compressed into tablets of mass 1071 mg and sufficient hardness.

Claims: WHAT WE CLAIM IS: 1. A compound of the formula I or their tautomeric forms, the attachment to the pyridine ring being in the 3- or 4-position, in which formula R^ stands for one or more substituents which can be the same or different and are selected from the group consisting of: hydrogen, halogen, trifluoromethyl, carboxy, C1-C4 alkyl, alkoxy or alkoxycarbonyl, nitro, amino or cyano and Q stands for C4-C20 divalent hydrocarbon radical which can be straight, branched, cyclic, saturated or unsaturated and X stands for carbonyl, carbonylamino, aminocarbonyl, oxycarbonyloxy, oxycarbonyl, carbonyloxy, aminocarbonyloxy, aminothio- carbonyloxy, oxycarbonylamino or oxythiocarbonylamino and Y stands for benzylene or phenylene and R2 stands for one or more substituents which can be the same or different and are selected from the group consisting of: hydrogen, C-1-C4 alkyl, hydroxyalkyl or alkoxy, hydroxy, halogen, triflouro- methyl, cyano, carboxamido, sulfamoyl, nitro, amino, carboxy, alkoxycarbonyl or benzyloxy; and pharmaceutically acceptable, non-toxic salts and N-oxides thereof. 2. A compound according to formula I of claim 1 , in which the attachment to the pyridine ring is in the 4-position, in which formula R1 stands for hydrogen and Q stands for C4-C12 divalent hydrocarbon radical which can be straight, branched, saturated or unsaturated and X stands for carbonyl, carbonylamino, aminocarbonyl, oxycarbonyloxy, oxycarbonyl, carbonyloxy, aminocarbonyloxy, aminothiocarbonyloxy, oxycarbonylamino or oxythiocarbonylamino and Y stands for benzylene or phenylene and R2 stands for one or more substituents which can be the same or different and are selected from the group consisting of: hydrogen, C-1-C4 alkyl or alkoxy, halogen, triflouromethyl or cyano; and pharmaceutically acceptable, non- toxic salts and N-oxides thereof. 3. A salt according to claim 1 in which the salt is selected from the group consisting of salts formed with hydrochloric, hydrobromic and hydro- iodic acid, phosphoric acid, sulphuric acid, nitric acid, p-toluenesulphonic acid, methanesulphonic acid, formic acid, acetic acid, propionic acid, citric acid, tartaric acid, and maleic acid, and lithium, sodium, potassium, magnesium, calcium salts, as well as salts with ammonia, C Cg-alkylamines, C- j -Cg alkanolamines, procaine, cycloalkylamines, benzylamines, and heterocyclic amines. 4. A compound of claim 1 which is selected from the group consisting of: Λ/-(6-benzoylaminohexyl)-/V-cyano-W'-4-pyridylguanidine; Λ/-(6-(4-chlorobenzoyloxy)hexyl)-Λ/ , -cyano-Λ/"-4-pyridylguanidine; A/-(5-(4-chlorobenzoyl)pentyl)-/V-cyano-A/"-4-pyridylguanidine ; Λ/-(7-(4-chlorobenzoyl)heptyl)-Λ/'-cyano-Λ/"-4-pyridylguanidine; and their salts and pure enantiomeric forms. 5. A pharmaceutical preparation, containing a compound accor- ding to any one of claims 1 - 4 alone or together with the necessary auxiliary agents. 6. A method of treating patients in need of treatment characterized in administering to said patients an effective amount of one or more com- pounds according to any of claims 1 - 5, if necessary together or concom- itantly with one or more other therapeutically active components. 7. A method according to claim 6 for the treatment and prophylaxis of disease states characterised in undesirable cell proliferation in e.g. skin cells and cancer cells . 8. Method for producing a compound of formula I according to claim 1 , in which a) a compound of the general formula II in which R- j , Q, X, Y and R2 are as defined above, is reacted with dicyclohexylcarbodiimide and cyanamide in the presence of triethylamine or another tertiary amine in acetonitrile or another inert solvent at room temperature or above; or b) a compound of the general formula III III in which R^ is as defined above, is reacted with a compound of the general formula IV IV in which Q, X, Y and R2 are as defined above, in the presence of triethylamine or another tertiary amine and 4-dimethylaminopyridine in pyridine or an inert solvent at room temperature or above; or c) a compound of the general formula V V R-l and Q are as defined above and A is oxygen, sulfur or nitrogen substituted by hydrogen, is reacted with a compound of the general formula VI Cl-B-Y-R 2 VI in which Y and R2 are as defined above and B is carbonyl or carbonyloxy, in pyridine or an inert solvent at 0°C or above. 9. The use of a compound of claim 1 in the manufacture of a medicament for the treatment and prophylaxis of a number of disease states, characterised by undesirable cell proliferation in e.g. skin cells and cancer cells.

Inventors: SCHOU CHARLOTTE, SCHOU, CHARLOTTE
Applicants: LEO PHARM PROD LTD, SCHOU CHARLOTTE, LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOEVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB), SCHOU, CHARLOTTE
Application year: 1998
Main classification: C07D213
IPC codes: A61K31, A61P17, A61P35, A61P43, C07D213